The first COVID-19 vaccine to reach clinical trials in humans was determined to be both safe and generate an immune response against the virus — a “milestone” in the battle to defeat the deadly bug, a new study found.
A single dose of the vaccine was found to produce virus-fighting antibodies and T cells, a type of immune cell, two weeks after it’s administered, according to the peer-reviewed study, published Friday in the journal The Lancet.
“These results represent an important milestone,” said the lead researcher on the study, Professor Wei Chen.
Producing both antibodies and T cells is an ideal result for a vaccine, the researchers said. A vaccine that does both not only triggers the body to produce virus-specific immune cells, but also supports the body’s innate immune response.
Comments